Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - STRATA Skin Sciences, Inc.Financial_Report.xls
EX-10.3 - EX-10.3 - STRATA Skin Sciences, Inc.d801327dex103.htm
EX-31.2 - EX-31.2 - STRATA Skin Sciences, Inc.d801327dex312.htm
EX-10.2 - EX-10.2 - STRATA Skin Sciences, Inc.d801327dex102.htm
EX-31.1 - EX-31.1 - STRATA Skin Sciences, Inc.d801327dex311.htm
EX-10.1 - EX-10.1 - STRATA Skin Sciences, Inc.d801327dex101.htm
EX-32.1 - EX-32.1 - STRATA Skin Sciences, Inc.d801327dex321.htm
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 000 — 51481

 

 

MELA SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   13-3986004

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

 

50 South Buckhout Street, Suite 1

Irvington, New York

  10533
(Address of Principal Executive offices)   (Zip Code)

Registrant’s Telephone Number, including area code:

(914) 591-3783

 

(Former name if changed since last report)

 

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “accelerated filer” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   ¨    Smaller reporting company   x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of October 31, 2014: 6,037,232 shares of the Registrant’s common stock were outstanding.

 

 

 


Table of Contents

MELA Sciences, Inc.

Table of Contents

 

     Page  

PART I. FINANCIAL INFORMATION

  

ITEM 1. Financial Statements

  

Condensed Balance Sheets as of September 30, 2014 (unaudited) and December 31, 2013

     1   

Condensed Statements of Operations (unaudited) for the three and nine month periods ended September  30, 2014 and 2013

     2   

Condensed Statements of Cash Flows (unaudited) for the nine month periods ended September  30, 2014 and 2013

     3   

Notes to Condensed Financial Statements (unaudited)

     4   

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     12   

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

     19   

ITEM 4. Controls and Procedures

     19   

PART II. OTHER INFORMATION

  

ITEM 1. Legal Proceedings

     19   

ITEM 1A. Risk Factors

     19   

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

     21   

ITEM 3. Defaults Upon Senior Securities

     21   

ITEM 4. Mine Safety Disclosures

     21   

ITEM 5. Other Information

     21   

ITEM 6. Exhibits

     21   

SIGNATURE

     22   

EXHIBIT INDEX

     23   


Table of Contents

PART I. FINANCIAL INFORMATION

 

ITEM 1.

MELA SCIENCES, INC.

CONDENSED BALANCE SHEETS

 

     September 30,     December 31,  
     2014     2013  
     (unaudited)     *  
ASSETS   

Current Assets:

    

Cash and cash equivalents

   $ 14,466,227      $ 3,782,881   

Accounts receivable (net of allowance of $43,080 and $46,130 as of September 30, 2014 and December 31, 2013, respectively)

     85,230        57,151   

Inventory (net of reserves of $1,401,333 as of September 30, 2014 and $325,000 as of December 31, 2013, respectively)

     5,363,787        5,631,205   

Prepaid expenses and other current assets

     617,185        879,698   
  

 

 

   

 

 

 

Total Current Assets

     20,532,429        10,350,935   

Property and equipment, net

     2,713,083        3,690,784   

Patents and trademarks, net

     37,988        41,795   

Deferred financing costs

     981,950        —     

Other assets

     48,000        48,000   
  

 

 

   

 

 

 

Total Assets

   $ 24,313,450      $ 14,131,514   
  

 

 

   

 

 

 
LIABILITIES AND STOCKHOLDERS’ EQUITY   

Current Liabilities:

    

Accounts payable (includes related parties of $70,711 and $32,902 as of September 30, 2014 and December 31, 2013, respectively)

   $ 1,271,877      $ 1,478,995   

Accrued expenses (includes related parties of $0 and $48,000 as of September 30, 2014 and December 31, 2013, respectively)

     1,010,666        844,131   

Deferred placement revenue

     85,278        243,605   

Warrant liability

     1,451,121        3,017,142   

Other current liabilities

     134,072        67,934   
  

 

 

   

 

 

 

Total Current Liabilities

     3,953,014        5,651,807   
  

 

 

   

 

 

 

Long-Term Liabilities:

    

Deferred placement revenue

     13,725        63,754   

Deferred rent

     90,093        120,120   

Senior secured convertible debentures, (net of discount of $9,967,564 and $0 as of September 30, 2014 and December 31, 2013, respectively)

     5,032,441        —     
  

 

 

   

 

 

 

Total Long-Term Liabilities

     5,136,259        183,874   
  

 

 

   

 

 

 

Total Liabilities

     9,089,273        5,835,681   
  

 

 

   

 

 

 

COMMITMENTS AND CONTINGENCIES

    

Stockholders’ Equity:

    

Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 12,300 at September 30, 2014 and 0 at December 31, 2013, respectively

     1,230        —     

Common stock - $0.001 par value; authorized 50,000,000 shares: issued and outstanding 5,217,742 shares at September 30, 2014 and 4,750,160 at December 31, 2013, respectively

     5,218        4,750   

Additional paid-in capital

     193,007,017        176,438,961   

Accumulated deficit

     (177,789,288     (168,147,878
  

 

 

   

 

 

 

Total Stockholders’ Equity

     15,224,177        8,295,833   
  

 

 

   

 

 

 

Total Liabilities and Stockholders’ Equity

   $ 24,313,450      $ 14,131,514   
  

 

 

   

 

 

 

 

* Derived from the audited balance sheet as of December 31, 2013

The accompanying notes are an integral part of these financial statements

 

1


Table of Contents

MELA SCIENCES, INC.

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

 

     Three months ended September 30,     Nine months ended September 30,  
     2014     2013     2014     2013  

Net revenues

   $ 217,902      $ 107,707      $ 540,695      $ 396,206   

Cost of revenue

     1,559,502        1,976,501        3,755,086        4,438,211   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross Profit

     (1,341,600     (1,868,794     (3,214,391     (4,042,005

Operating expenses:

        

Research and development

     344,525        856,764        1,422,997        3,241,727   

Selling, general and administrative

     2,314,712        3,480,689        8,353,793        12,440,457   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     2,659,237        4,337,453        9,776,790        15,682,184   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating Loss

     (4,000,837     (6,206,247     (12,991,181     (19,724,189

Other income (expenses):

        

Interest income

     3,874        2,508        5,180        7,323   

Interest expense

     (530,542     (222,758     (532,899     (563,143

Change in fair value of warrant liability

     2,108,106        —          7,150,886        (89,859

Write-off of unamortized loan costs

     —          (983,330     —          (983,330

Gain on sale of fixed assets

     11,000        —          15,740        —     

Registration rights liquidated damages

     —          —          (3,419,698     —     

Other income, net

     120,537        5,400        130,562        15,400   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total Other Income/(Loss)

     1,712,975        (1,198,180     3,349,771        (1,613,609
  

 

 

   

 

 

   

 

 

   

 

 

 
        
  

 

 

   

 

 

   

 

 

   

 

 

 

Net Loss

   $ (2,287,862   $ (7,404,427   $ (9,641,410   $ (21,337,798
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic net loss per common share

   $ (0.44   $ (1.72   $ (1.89   $ (5.10
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted net loss per common share

   $ (0.44   $ (1.72   $ (1.89   $ (5.10
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic weighted average number of common shares outstanding

     5,216,290        4,312,118        5,108,418        4,182,814   
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted weighted average number of common shares outstanding

     5,216,290        4,312,118        5,108,418        4,182,814   
  

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these financial statements

 

2


Table of Contents

MELA SCIENCES, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited)

 

     Nine months ended September 30,  
     2014     2013  

Cash flows from operating activities:

    

Net loss

   $ (9,641,410   $ (21,337,798

Adjustments to reconcile net loss to net cash used in operating activities:

    

Write-off of unamortized loan costs

     —          983,330   

Depreciation and amortization

     1,370,802        1,790,037   

Impairment of long-lived assets

     —          1,010,712   

Bad debt expense

     700        52,097   

Write-off of unamortized financing costs

     —          41,166   

Stock-based compensation

     447,295        1,256,754   

Amortization of deferred financing costs

     37,689        163,569   

Inventory reserves

     1,076,333        325,000   

Change in fair value of warrant liability

     (7,150,886     89,859   

Amortization of debt discount

     385,359        —     

Gain on sale of fixed assets

     (15,740     —     

Changes in operating assets and liabilities:

    

Accounts receivable

     (28,779     76,944   

Inventory

     (1,362,391     79,014   

Melafind® systems sold

     162,922        —     

Prepaid expenses and other current assets

     262,513        300,528   

Other assets

     —          4,000   

Accounts payable and accrued expenses

     (40,583     (503,345

Other current liabilities

     66,138        17,017   

Deferred revenue

     (208,356     69,364   

Deferred rent

     (30,027     (17,739

Long-term interest payable

     —          86,042   
  

 

 

   

 

 

 

Net cash used in operating activities

     (14,668,421     (15,513,449
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property and equipment

     —          (4,865,358

Proceeds from the sale of fixed assets

     17,000        —     
  

 

 

   

 

 

 

Net cash provided by (used in) investing activities

     17,000        (4,865,358
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Net proceeds from private placements/public offerings

     11,457,831        15,789,873   

Proceeds from long-term debt

     15,000,005        6,000,000   

Expenses related to borrowings and issuance of warrant

     (1,123,069     (245,358

Repayment of long-term debt

     —          (6,425,000

Proceeds from exercise of stock options

     —          18,059   
  

 

 

   

 

 

 

Net cash provided by financing activities

     25,334,767        15,137,574   
  

 

 

   

 

 

 

Net increase/(decrease) in cash and cash equivalents

     10,683,346        (5,241,233

Cash and cash equivalents at beginning of period

     3,782,881        7,861,524   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 14,466,227      $ 2,620,291   
  

 

 

   

 

 

 

Non-cash investing and financing activity:

    

Reclassification of warrant liability to stockholders’ equity

   $ —        $ 652,442   

Recognition of debt discount on long-term debt

   $ 5,787,573      $ —     

Recognition of beneficial conversion feature on long-term debt

   $ 4,565,350      $ —     

Exchange of series A convertible preferred stock for series B convertible preferred stock

   $ 12,300,000      $ —     

The accompanying notes are an integral part of these financial statements

 

3


Table of Contents

MELA SCIENCES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

1. ORGANIZATION AND BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements of MELA Sciences, Inc., a Delaware corporation (“MELA” or the “Company”), have been prepared in accordance with the instructions to Form 10-Q and therefore do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“GAAP”); however, such information reflects all adjustments (consisting solely of normal recurring adjustments) that are, in the opinion of management, necessary for a fair statement of the results for the interim periods.

The condensed financial statements should be read in conjunction with the consolidated financial statements and notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. In addition, some of the Company’s statements in this Quarterly Report on Form 10-Q may involve risks and uncertainties that could significantly impact expected future results. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of results to be expected for the full year.

The Company is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. The Company is primarily focused on the commercialization of its flagship product, the MelaFind® system, and the further design and development of MelaFind® and its technology. The MelaFind® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. It features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been “trained” and blind tested on the Company’s proprietary database of melanomas and benign lesions. The MelaFind® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion.

In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval. In March 2012, the Company installed the first commercial MelaFind® systems, and proceeded with the commercial launch of MelaFind®. The Company is currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using the MelaFind® system with their performance if MelaFind® was not available.

The launch of MelaFind® in 2012 and the subsequent commercialization activities supporting the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013. In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, the Company adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. The Company also changed its business model for the MelaFind® system from a rental-based to a sales-based model. The Company has reduced its costs, added more experience to its management team, and reorganized its sales and marketing activities.

On August 22, 2013, the Company received a notice from The NASDAQ Stock Market (“NASDAQ”) that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. In July 2014, the Company effected a one-for-ten reverse split of its common stock in order to regain compliance with the minimum bid price requirement prior to the expiration of the last applicable grace period. On July 24, 2014, the Company was notified by NASDAQ that it is now in compliance with the minimum bid price requirement.

In July 2014, MELA announced that it took the first step in the process of obtaining insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (“MSDSLA”) procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection of melanoma. The Company submitted an application for a Current Procedural Terminology (“CPT®”) code, which is necessary for Medicare Part B reimbursement by the Centers for Medicare and Medicaid Services (“CMS”). Currently, there is no CPT® code available for the MelaFind® process. The Company plans to commence efforts to obtain reimbursement from private insurers during the CMS’ coverage determination process. Coverage could become available as early as January 2016.

MELA has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As a result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to operate and to meet its obligations in the ordinary course of business. In February 2014, the Company raised net proceeds of approximately $11.5 million from the sale of Series A convertible preferred stock and warrants to purchase common stock to strengthen the Company’s financial position (see Footnote 11 “STOCKHOLDERS’ EQUITY”). In July 2014, the Company issued Series B convertible preferred stock, senior secured convertible debt and warrants (see Footnote 9 “DEBT”). The Company raised an additional $13.8 million in net proceeds from this offering. The proceeds from the sale of the Series B convertible preferred stock were used to redeem all outstanding shares of Series A convertible preferred stock.

 

4


Table of Contents

The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Interim results may not be indicative of the results that may be expected for the year. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all of its cash resources to the development and marketing of the MelaFind® system and general and administrative expenses, and to date it has not generated any significant revenues from the sale of products. As a result, MELA has an accumulated deficit of $177,789,288 as of September 30, 2014. The Company’s recurring losses from operations and the accumulated deficit raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Even if the Company succeeds in commercializing the MelaFind® system it may never become profitable. The Company expects to continue to incur significant losses over the next several years.

2. USE OF ESTIMATES

The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to inventory reserves, stock-based compensation arrangements, and the warrant liability. Actual results could differ from these estimates. Estimates of future operating results are based upon numerous factors including past experience, known information and subjective estimates and assumptions. Actual future operating results could be materially different from management’s estimates and unforeseen events could adversely affect management’s estimates.

3. RECENT ACCOUNTING PRONOUNCEMENTS

In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU” No. 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for annual periods ending after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company’s results of operations, cash flows or financial condition.

In May 2014, the FASB issued ASU No. 2014-09,Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016 and interim periods within those periods. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

4. INVENTORY

Inventories currently consist of MelaFind® systems, work in process components and other finished products and accessories that are stated at the lower of cost or market value. Inventory accessories are purchased items to be sold for use in the operation of the MelaFind® systems. The Company maintains a reserve for specific inventory items that are no longer being used in the devices.

During the quarter ended September 30, 2014, the Company replaced the Hand-held Imager’s “Field Phantom” imaging test with the “Flap Shutter” imaging test. The new Flap Shutter test utilizes an internal imaging target within each Hand-held Imager. This new test process eliminates the need for the external Field Phantom imaging test fixture; thereby reducing manufacturing material costs, test labor and cycle time. Additionally, an improvement to the Hand-held Imager’s overall reliability is anticipated by eliminating human error associated with the previous Field Phantom imaging test process. As a result, the Phantom Fixture has become obsolete and an additional $537,774 was added to the reserve for obsolete inventory.

In December 2013, the Company changed its business model for the MelaFind® system from a rental-based model to a sales-based model. In accordance with this new sales model, the Company reclassified $5,401,866 of MelaFind® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent systems available for sale.

During the second quarter of 2014, the Company deferred repairs of certain of its MelaFind system units that it determined were unlikely to be sold during the next several periods. The Company estimated the cost to restore its system units to sellable condition and created a repair reserve amounting to $538,559 at September 30, 2014.

 

5


Table of Contents

On August 6, 2014, the Company and Askion GmbH entered into an “Amended and Restated Askion Production Agreement.” This agreement is a mutual settlement and release agreement of two prior unfulfilled purchase orders. The settlement amount of $1,142,512 was used for inventory purchases which consist primarily of Hand-held Imager assemblies.

Inventory consists of the following:

 

     September 30,     December 31,  
     2014     2013  

MelaFind® Systems

   $ 4,240,506      $ 4,858,088   

Hand-held Imager assemblies

     1,142,512        —     

Components

     858,377        543,778   

Mela record cards

     326,660        327,900   

Accessories

     197,065        226,439   
  

 

 

   

 

 

 
     6,765,120        5,956,205   

Reserve for obsolete inventory

     (862,774     (325,000

Reserve for inventory repairs

     (538,559     —     
  

 

 

   

 

 

 
   $ 5,363,787      $ 5,631,205   
  

 

 

   

 

 

 

5. PROPERTY AND EQUIPMENT, NET

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when its carrying amount exceeds the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value.

In December 2013, the Company changed its business model for the MelaFind® system from a rental-based to a sales-based model. In accordance with this new sales model, the Company reclassified $5,401,866 of MelaFind® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent systems available for sale. Systems that have been leased under the rental-based model remain in property and equipment.

During the nine months ended September 30, 2014, the Company reclassified $725,598 of accumulated depreciation related to MelaFind system components that were previously leased and are now available for sale that were included in inventory at December 31, 2013.

Property and equipment, at cost, consists of the following:

 

     September 30,     December 31,     Estimated  
     2014     2013     Useful Life  

Leasehold improvements

   $ 905,888      $ 905,888        Lease Term   

Laboratory and research equipment

     1,083,661        1,083,661        3-5 years   

Office furniture and equipment

     1,969,454        2,022,833        3-5 years   

MelaFind® Systems

     4,031,190        5,081,816     
  

 

 

   

 

 

   
     7,990,193        9,094,198     

Accumulated depreciation and amortization

     (5,277,110     (5,403,414  
  

 

 

   

 

 

   
   $ 2,713,083      $ 3,690,784     
  

 

 

   

 

 

   

Depreciation expense for the three and nine months ended September 30, 2014 was $487,998 and $1,366,995, respectively, and for the three and nine months ended September 30, 2013 was $681,759 and $1,785,793, respectively.

6. NET LOSS PER COMMON SHARE

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of September 30, 2014 and September 30, 2013 consist of common stock equivalents of convertible preferred stock, senior secured convertible debentures, common stock purchase warrants and common stock options, which are summarized as follows:

 

     September 30,  
     2014      2013  

Common stock equivalents of convertible preferred stock

     4,795,321         —     

Common stock equivalents of convertible debentures

     5,847,955         —     

Common stock purchase warrants

     13,078,920         89,321   

Common stock options

     320,349         255,635   
  

 

 

    

 

 

 

Total

     24,042,545         344,956   
  

 

 

    

 

 

 

 

6


Table of Contents

7. COMPREHENSIVE LOSS

For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statement of Operations and comprehensive net loss and related per share amounts.

8. STOCK-BASED COMPENSATION

Stock awards under the Company’s stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant.

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

 

     September 30,
     2014   2013

Expected life

   6.5 years   5.5-6.5 years

Expected volatility

   75.51-73.87%   71.71%-76.83%

Risk-free interest rate

   2.14-2.45%   .71-2.04%

Dividend yield

   —     —  

Stock-based compensation expense for the three and nine months ended September 30, 2014 was $115,180 and $447,295, respectively, and for the three and nine months ended September 30, 2013 was $159,621 and $1,256,754, respectively.

9. DEBT

On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with institutional investors (the “Investors”) providing for the issuance of (i) 12,300 shares of Series B convertible preferred stock, par value $0.10 and a stated value of $1,000 per share (the “Series B Preferred Stock”), (ii) Senior Secured Convertible Debentures in the aggregate principal amount of $15,000,005, due, subject to the terms therein, in July 2019 (the “Debentures”), (iii) warrants (the “July 2014 Series A Warrants”) to purchase up to an aggregate of 6,198,832 shares of common stock, $0.001 par value per share (the “Common Stock”), at an exercise price of $2.45 per share expiring in July 2019 issued to the investors in the Debentures, and (iv) warrants (the “July 2014 Series B Warrants”) to purchase up to an aggregate of 4,795,321 shares of Common Stock at an exercise price of $2.45 per share expiring in January 2016 issued to investors in the Series B Preferred Stock (the “Offering”). The Offering closed on July 24, 2014. Proceeds from the Debentures will be used for general working capital purposes.

The Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of Common Stock. The Debentures are convertible at any time into an aggregate of 5,847,955 shares of Common Stock at an initial conversion price of $2.565 per share (which represents a price above the closing bid price of the Common Stock on July 18, 2014, the trading day immediately prior to the entry into the Purchase Agreement). The Company’s obligations under the Debentures are secured by a first priority lien on all of the Company’s intellectual property pursuant to the terms of a security agreement (“Security Agreement”) dated July 21, 2014 among the Company and the investors. The Preferred Stock is only entitled to dividends in the event that dividends are paid on the Common Stock, and the Preferred Stock will not have any preferences over the Common Stock, including liquidation rights. The warrants are also subject to certain ownership limitations and are immediately exercisable.

 

7


Table of Contents

In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company was obligated to file a registration statement to register for resale the shares of Common Stock issuable upon conversion of the Series B Preferred Stock and Debentures and upon exercise of the Warrants. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on August 19, 2014, which was declared effective by the SEC on October 20, 2014 (File No. 333-198249).

For financial reporting purposes, the $15,000,005 funded by the Investors on July 21, 2014 was allocated first to the fair value of the obligation to issue the Warrants, which totaled $5,296,345, then to the intrinsic value of the beneficial conversion feature on the Debentures of $4,565,350 and then the balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491,228, resulting in an initial carrying value of the Debentures of $4,647,082. The initial debt discount on the Debentures totaled $10,352,923 and will be amortized over the five year life of the Debentures. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligations, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. The fair value of the warrant obligation was determined using an option pricing model that used various assumptions including: a stock price of $2.44 per share, volatility of 93.46%, time to maturity of 5.0 years, exercise price of $2.45 per share and a risk free interest rate of return of 1.62%.

On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc. (“Hercules”), a venture capital lender, whereby the Company borrowed $6,000,000 (the “Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules $6,400,000, including the end of term fee of $425,000, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty of $180,000.

Upon executing the loan documents on March 15, 2013, the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share were not fixed on March 15, 2013, but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 69,321 shares of common stock at an exercise price of approximately $11.20 per share. The warrant expires on April 26, 2018.

For financial reporting purposes, the $6,000,000 funded by the Lender on March 15, 2013 was allocated first to the fair value of the obligation to issue the warrant, which totaled approximately $563,000, and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5,300,000. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of $89,859 are included in operating results for the nine months ended September 30, 2013. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $11.60 to $11.80 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $11.50 to $11.60 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value.

The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727,000. The terms of the Loan required us to pay the Lender a fee of $425,000 at the maturity of the Loan. The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant was classified within stockholders’ equity.

As the result of the Company electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed at that date were $983,330.

10. REVERSE SPLIT OF COMMON STOCK

On July 9, 2014, the Company effected a previously authorized 1-for-10 reverse stock split of its common stock. The reverse split took effect at the start of trading on July 10, 2014 on a 1-for-10 split basis. All prior periods have been retroactively adjusted to reflect the reverse stock split. The par value of the common stock did not change.

 

8


Table of Contents

11. STOCKHOLDERS’ EQUITY

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors.

On July 24, 2014, in connection with the Offering (see Note 9 “DEBT”), the Company issued to certain investors 12,300 shares of Series B Convertible Preferred Stock at a price of $1,000 per share convertible into Common Stock at an initial price of $2.565 per share and Series B Warrants to purchase up to an aggregate of 4,795,321 shares of Common Stock at an exercise price of $2.45 per share, expiring in January 2016. The Preferred Stock is convertible into an aggregate of 4,795,321 shares of Common Stock. Holders of the Preferred Stock are entitled to dividends only in the event that dividends are paid on the Common Stock, and the Preferred Stock has no preferences over the Common Stock, including liquidation rights. The Preferred Stock and the July 2014 Series A Warrants are immediately exercisable and are subject to certain ownership limitations.

For financial reporting purposes, the $12,300,000 preferred stock value was allocated first to the fair value of the July 2014 Series B warrants, which totaled $2,486,780, then to the intrinsic value of the beneficial conversion feature of $1,887,364. The amount of the beneficial conversion feature is considered to be a deemed dividend on the date of issuance to the Series B preferred stockholders due to the July 2014 Series B warrants being immediately exercisable. The deemed dividend was accounted for as a movement within additional paid-in capital. The following table represents the net loss attributable to common stockholders after giving effect for the deemed dividend:

 

     Three months ended
September 30, 2014
    Nine months ended
September 30, 2014
 

Net loss

   $ (2,287,862   $ (9,641,410

Series B preferred stock beneficial conversion feature

     (1,887,364     (1,887,364
  

 

 

   

 

 

 

Net loss attributable to common stockholders

   $ (4,175,226   $ (11,528,774
  

 

 

   

 

 

 

Basic and diluted net loss per common share

   $ (0.80   $ (2.26
  

 

 

   

 

 

 

Basic and diluted weighted average number of commons shares outstanding

     5,216,290        5,108,418   
  

 

 

   

 

 

 

Pursuant to the terms of the Purchase Agreement, the Series A Convertible Preferred Stock was redeemed from the proceeds of the Series B Convertible Preferred Stock. In September 2014, the Company amended the registration statement related to the Series A Preferred Stock to deregister those shares that would have been issuable upon conversion of the Series A Preferred Stock had it not already been redeemed by the proceeds of the Series B Preferred Stock.

On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold to the Purchasers (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share (the “Series A Preferred Stock”), convertible into 1,464,287 shares of common stock at an initial conversion price of $8.40, and (ii) warrants to purchase up to 1,329,731 shares of common stock for net proceeds of $11,457,831. The warrants have an exercise price of $7.40 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014. They will be recorded at their respective fair value at each subsequent balance sheet date. The fair value of these warrants on September 30, 2014 was approximately $957,406. The change in fair value of these warrants for the three and nine months ended September 30, 2014 was a benefit of $1,436,107 and $4,627,459, respectively (see footnote 12 “FAIR VALUE OF FINANCIAL INSTRUMENTS”).

In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of $3,419,698. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.

On July 21, 2014, the Company entered into the Purchase Agreement and issued, among other things, the Series B Preferred Stock (See Footnote 9 “DEBT”). In connection with the issuance of the Series B Preferred Stock, the Company redeemed all 12,300 shares of Series A Preferred Stock. In September 2014, the Company amended the registration statement related to the Series A Preferred Stock (File No. 333-194649) to deregister those shares that would have been issuable upon conversion of the Series A Preferred Stock.

Common Stock

The Company is authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share.

On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6,000,000 registered offering of 422,819 shares of the Company’s common stock, fully paid prefunded Series B Warrants to purchase up to 434,325 shares of its common stock and additional warrants (“October 2013 Series A Warrants”) to purchase up to 685,715 shares of its common stock. The October 2013 Series A Warrants are exercisable beginning on May 1, 2014 at a price of $8.50 per share and expire on May 1, 2019. The prefunded Series B Warrants are exercisable immediately for no additional consideration. The offering closed on October 31, 2013.

The holders exercised all of the prefunded Series B warrants in March 2014. There were no warrant exercises in the first nine months of 2013.

The October 2013 Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The fair value of these warrants on September 30, 2014 was approximately $493,715. The change in fair value of these warrants for the three and nine months ended September 30, 2014, was a benefit of $671,999 and $2,523,427, respectively (see footnote 12 “FAIR VALUE OF FINANCIAL INSTRUMENTS”).

 

9


Table of Contents

On August 22, 2013, the Company received a notice from NASDAQ that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. In July 2014, the Company effected a one-for-ten reverse split of its common stock in order to regain compliance with the minimum bid price requirement prior to the expiration of the last applicable grace period. On July 24, 2014, the Company was notified by NASDAQ that it is now in compliance with the minimum bid price requirement.

Outstanding common stock warrants consist of the following:

 

Issue Date

   Expiration Date      Total
Warrants
     Ex. Price  

  4/26/2013

     4/26/2018         69,321       $ 11.18   

10/31/2013

     4/30/2019         685,715       $ 8.50   

    2/5/2014

     2/5/2019         1,329,731       $ 7.40   

  7/24/2014

     7/24/2019         6,198,832       $ 2.45   

  7/24/2014

     1/24/2016         4,795,321       $ 2.45   
     

 

 

    
        13,078,920      
     

 

 

    

During the three months ended September 30, 2014, the number of outstanding shares of the Company’s common stock increased from 5,213,969 to 5,217,742.

12. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:

 

    Level 1: Observable inputs such as quoted prices in active markets;

 

    Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

 

    Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company’s financial instruments are cash and cash equivalents, accounts payable, and derivative warrant liabilities. The recorded values of cash equivalents and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.

The warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and therefore are classified as a derivative. These warrants have been recorded at their fair value using an option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date.

 

10


Table of Contents

A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of September 30, 2014 and December 31, 2013 is as follows:

 

     September 30, 2014     December 31, 2013  

Stock Price

   $ 1.72      $ 6.40   

Risk-free Rate (5-year U.S. Treasury Yield)

     1.76     1.75

Volatility (Annual)

     93.46     93.43

Time to Maturity (Years)

     4.35-4.58        5.33   

Derivative warrant liabilities consist of the following:

 

     Fair Value
Measurements Using
Significant
Unobservable Inputs
(Level 3)
 

Beginning balance at January 1, 2014

   $ 3,017,142   

Issuance of warrants in February 2014

     5,584,865   

Changes in estimated fair value

     (7,150,886
  

 

 

 

Ending balance at September 30, 2014

   $ 1,451,121   
  

 

 

 

13. SUBSEQUENT EVENTS

In October 2014, 513 shares of Convertible Preferred Stock were converted into 200,000 shares of common stock, and $1,588,992 of Convertible Debentures were converted into 619,490 shares of common stock.

 

11


Table of Contents

ITEM 2.

MELA SCIENCES, INC.

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition and results of operations is intended to provide information to help you better understand and evaluate our financial condition and results of operations. We recommend that you read this section in conjunction with our unaudited condensed financial statements and accompanying notes included under Part I, Item 1 of this Quarterly Report and our financial statements and accompanying notes in our Annual Report on Form 10-K for the year ended December 31, 2013. We have experienced and expect to continue to experience volatility in our operating loss resulting from the MelaFind® system activities that can vary significantly period-to-period. Therefore we believe that period-to-period comparisons of our historical results of operations may not be meaningful and should not be relied on as indicative of our future performance.

This quarterly report on Form 10-Q, including the following discussion and analysis of financial condition and results of operations, contains forward-looking statements that you should read in conjunction with the financial statements and notes to financial statements that we have included elsewhere in this report. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Words such as “believe”, “anticipate,” “expect,” “intend,” “plan,” “will,” “may” “should,” “estimate,” “predict,” “potential,” “continue,” or the negative of such terms or other similar expressions, identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. Factors that might cause such a difference include those discussed below under the heading “Risk Factors,” as well as those discussed elsewhere in this quarterly report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2013. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

Overview

We are a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. We primarily focus on the commercialization of our flagship product, the MelaFind® system, and the further design and development of MelaFind® and its technology. The MelaFind® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. It features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been “trained” and blind tested on our proprietary database of melanomas and benign lesions. The MelaFind® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion.

In November 2011, we received written approval from the FDA for the MelaFind® PMA application and in September 2011, we received CE Mark approval. In March 2012, we installed the first commercial MelaFind® systems, and proceeded with the commercial launch of MelaFind®. We are currently conducting a PAS evaluating the sensitivity and false positive rate of physicians after using the MelaFind® system with their performance if MelaFind® was not available.

The launch of MelaFind® in 2012 and the subsequent commercialization activities supporting the launch did not meet our initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013. In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, we adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. We also changed our business model for the MelaFind® system from a rental-based to a sales-based model. We have reduced costs, added more experience to our management team, and reorganized our sales and marketing activities.

On August 22, 2013, we received a notice from The NASDAQ that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. In July 2014, we effected a one-for-ten reverse split of our common stock in order to regain compliance with the minimum bid price requirement prior to the expiration of the last applicable grace period. On July 24, 2014, we were notified by NASDAQ that we are now in compliance with the minimum bid price requirement.

 

12


Table of Contents

In July 2014, we announced that we took the first step in the process of obtaining insurance reimbursement for our MSDSLA procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection of melanoma. We submitted an application for a CPT® code, which is necessary for Medicare Part B reimbursement by the CMS. Currently, there is no CPT® code available for the MelaFind® process. We plan to commence efforts to obtain reimbursement from private insurers during the CMS’ coverage determination process. Coverage could become available as early as January 2016.

Until we complete our transition from a lease-based to sales-based revenue model and obtain insurance reimbursement from the CMS and private insurers, we expect that our revenues will not be sufficient to cover our expected operating and other expenses. Our financial success will depend on a number of factors, primary among which is our ability to sell MelaFind® systems, increase the penetration with dermatologists, encourage the usage of these systems, and control our costs. Currently, we cannot determine when we will have sufficient revenues to cover our continuing developmental costs, manufacturing, marketing and other operational expenses.

During 2014, as part of our marketing efforts to increase awareness of MelaFind and to provide support for our CPT code application and insurance reimbursement, we sponsored four “reader” studies conducted in the U.S. and one in Germany that measured the impact of MelaFind on physician biopsy management and supported the use of MelaFind as a tool to improve the dermatologist’s overall accuracy in finding more melanomas and in reducing the number of benign biopsies. In October 2014, we announced that in the 2013 Outcomes for Cleveland Clinic’s Dermatology & Plastic Surgery Institute report, the use of MelaFind reduced by 61% benign biopsies of the clinically suspicious pigmented lesions in an at-risk population, indicating that MelaFind analysis may prevent overly aggressive biopsy decisions. We believe the reader studies and the Cleveland Clinic report add to the growing body of evidence of MelaFind’s value as an imager and analytical tool for the medical dermatologist in the diagnosis of melanoma.

We are committed to enhancing the capabilities of the MelaFind® system. Based on the insights from our key opinion leaders and feedback from our users, we are transitioning MelaFind® from a melanoma scoring technology to a dermal imaging and metrics clinical tool. We are also considering the broadening of our target market beyond clinical dermatologists. Our long-term goal is to be an information exchange company, with a focus on optically gathering data that can improve the diagnosis of various cancers, enable better patient care, improve efficiency and reduce costs. The scope and the speed of the implementation of these new strategies will depend on our financial and human resources and ultimately the acceptance of our products in the marketplace.

During the third quarter of 2014, we replaced the Hand-held Imager’s “Field Phantom” imaging test with the “Flap Shutter” imaging test. The new Flap Shutter test utilizes an internal imaging target within each Hand-held Imager. This new test process eliminates the need for the external Field Phantom imaging test fixture; thereby reducing manufacturing material costs, test labor and cycle time. Additionally, an improvement to the Hand-held Imager’s overall reliability is anticipated by eliminating human error associated with the previous Field Phantom imaging test process.

Our PAS is evaluating the sensitivity and false positive rate of physician’s after using the MelaFind® system with their performance if MelaFind was not available. On October 17, 2013, the FDA notified us that our report with respect to the PAS was inadequate to allow the agency to complete its review, and as a result the FDA revised the PAS status on its website to “Progress Inadequate.” In January 2014, a revised enrollment plan and schedule was approved by the FDA and the interactive review process was closed. On April 2, 2014, the FDA updated the study status to “Progress Adequate” and approved our new study timeline. We currently target submission of the PAS report to the FDA by year-end 2018.

Liquidity and Capital Resources

Since our inception, we have generated significant losses. As of September 30, 2014, we had an accumulated deficit of approximately $177.8 million. We expect to continue to invest in the further development of the MelaFind® system, clinical trials and medical conferences. We anticipate that we will continue to incur net losses for the foreseeable future as the commercial launch of the MelaFind® system continues and as we conduct the PAS.

In February 2014, we sold to two investors for net proceeds of $11.4 million (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, convertible into 1.5 million shares of common stock at a conversion price of $8.40, and (ii) warrants to purchase up to 1.3 million shares of the Company’s common stock. These investors have been granted rights of participation in future offerings of our securities for one year. In addition, as a condition of the financing, our directors purchased an aggregate of 20,271 shares of Common Stock, at a price of $7.40 per share, for aggregate gross proceeds of $150,000.

In connection with this financing, we also granted to the Purchasers resale registration rights with respect to the shares of Common Stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Series A investors were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014.

In July 2014, we raised additional net proceeds of approximately $13.8 million through the issuance of 4% senior secured convertible debentures due July 2019, Series B convertible preferred stock and warrants to purchase common stock. The debentures are convertible at any time into an aggregate of approximately 5.8 million shares of our Common Stock at a price of $2.565 per share. Our obligations under the debentures are secured by a first priority lien on all of our intellectual property. In connection with the transaction, we also issued 12,300 shares of Series B Preferred Stock, convertible at any time into an aggregate of approximately 4.8 million shares of common stock at a conversion price of $2.565 per share. Proceeds from the sale of the Series B Preferred Stock were used to redeem all of our outstanding Series A Preferred Stock that was issued in February 2014. We also issued warrants to purchase Common Stock at an exercise price of $2.45 per share, with 4.8 million

 

13


Table of Contents

warrants expiring in eighteen months from the date of issuance, and 6.2 million warrants expiring five years from the date of issuance. We entered into a Registration Rights Agreement with the investors pursuant to which we were obligated to file a registration statement to register the resale of the shares of Common Stock issuable upon conversion of the Series B Preferred Stock and Debentures and upon exercise of the warrants. The registration statement was declared effective in October 2014. In September 2014, we amended the registration statement related to the Series A Preferred Stock to deregister those shares that would have been issuable upon conversion of the Series A Preferred Stock.

We have experienced recurring losses and negative cash flow from operations. These recurring losses raise substantial doubt about our ability to continue as a going concern. We expect these conditions to continue for the foreseeable future. As the result of these factors, we have been and continue to be dependent on raising capital from the sale of securities in order to continue to operate and to meet our obligations in the ordinary course of business. We may need to raise funds in the future to support our sales and marketing of the MelaFind® system, further advances in the MelaFind® technology and to support clinical trials. The timing and amount of any additional funding we may seek will be affected by numerous factors, many of which are not under our control, including market acceptance of the MelaFind® system. There can be no assurance that additional financing will be available in the future at an acceptable cost, or at all.

Results of Operations

Three Months Ended September 30, 2014 Compared with Three Months Ended September 30, 2013

Revenue

Revenue increased 100% to $0.2 million in the three months ended September 30, 2014 compared with $0.1 million in the three months ended September 30, 2013. The increase of $0.1 million is primarily the result of new MelaFind® system sales offset by a decrease in placement and usage fees from prior quarter due to the change in our business model from a lease-based model to a sales-based model.

Cost of Revenue

Costs of revenue decreased to approximately $1.6 million in the three months ended September 30, 2014, compared with $2.0 million in the three months ended September 30, 2013. This decrease of $0.4 million or 20% is primarily due to an impairment charge of approximately $1.0 million taken in the third quarter of 2013, offset by an increase in the reserve for obsolete inventory of approximately $0.5 million in the third quarter of 2014 resulting from an improvement in the Hand-hand Imager that rendered the Field Phantom imaging test fixture obsolete. Cost of revenue during the quarter also consisted of the cost of sold MelaFind® systems, warranty reserves, repairs of system components, cost of consumables, technical support costs and depreciation expense of the existing MelaFind® systems leased to customers.

Research and Development Expense

Research and development (“R&D”) expenses decreased to $0.3 million in the three months ended September 30, 2014 compared with $0.9 million in the three months ended September 30, 2013. The decrease of $0.6 million or approximately 67% is the result of salary and headcount reductions and a reduction in product improvement expenses. Ongoing R&D efforts are for product enhancements and are expected to trend upward over the next several quarters. In August 2014, we announced a collaboration with Columbia University to explore potential next generation Melafind enhancements to the system’s range and use.

Selling, General and Administrative Expense

Selling, general and administrative expenses (“SG&A”) decreased to $2.3 million in the three months ended September 30, 2014 from $3.5 million in the three months ended September 30, 2013. The decrease of $1.2 million or 34% is the result of salary and headcount decreases, a reduction in stock-based compensation expense and further cost reduction initiatives. We plan to institute further actions that may further reduce our quarterly levels of SG&A expense.

Interest Expense

Interest expense for the three months ended September 30, 2014 is $0.5 million compared with $0.2 million in the three months ended September 30, 2013 and currently represents interest expense on the 4% Senior Convertible Debentures issued in July 2014 and the amortization of the related debt discount compared with the interest and other expenses related to the loan from Hercules Technology entered into in March 2013 and paid in full on September 10, 2013 (See Footnote 9 “DEBT”).

Change in Fair Value of Warrant Liability

The change in fair value of our warrant liability is a benefit of $2.1 million for the three months ended September 30, 2014. There was no warrant liability recorded for the three months ended September 30, 2013. The current benefit is directly related to the reduction in the Company’s stock price for the period.

 

14


Table of Contents

Other Income

Other income for the three month periods ended September 30, 2014 and 2013 was $0.1 million and $5,000, respectively, and is royalty income we earn each quarter from Kavo Dental GmbH on the sale/licensing of our DIFOTI product. During the three months ended September 30, 2014, we received back royalty payments on actual unit sales compared with the minimum royalty payment of $5,000 per quarter we recorded in 2013.

Nine Months Ended September 30, 2014 Compared with Nine Months Ended September 30, 2013

Revenue

Revenue increased to $0.5 million in the nine months ended September 30, 2014 compared with $0.4 million in the nine months ended September 30, 2013. The increase of $0.1 million is the direct result of our change in business strategy from a lease-based model to a sales-based model, which resulted in MelaFind® system sales for the nine months ended September 30, 2014 of $0.3 million offset by a decrease in deferred placement revenue and lower usage revenue as compared to the nine months ended September 30, 2013.

Cost of Revenue

Costs of revenue decreased to $3.8 million in the nine months ended September 30, 2014, compared with $4.4 million in the nine months ended September 30, 2013. This decrease of $0.6 million is primarily due to an impairment charge of approximately $1.0 million taken in 2013, offset by an increase in the reserve for obsolete inventory of approximately $0.5 million recorded in 2014 due to an improvement in the Hand-hand Imager that rendered the Field Phantom imaging test fixture obsolete. Additional decreases in cost were due to salary and headcount reductions in the nine months ended September 30, 2014 compared with prior period. Cost of revenue during the quarter also consisted of the cost of sold MelaFind® systems, warranty reserves, repairs of system components, cost of consumables, technical support costs and depreciation expense of the MelaFind® systems leased to customers.

Research and Development Expense

R&D expenses decreased to $1.4 million in the nine months ended September 30, 2014 compared with $3.2 million in the nine months ended September 30, 2013. The decrease of $1.8 million is the result of salary and headcount reductions and a reduction in product improvement expenses. Ongoing R&D efforts are for MelaFind product enhancements.

Selling, General and Administrative Expense

SG&A decreased to $8.4 million in the nine months ended September 30, 2014 from $12.4 million in the nine months ended September 30, 2013. The decrease of $4.0 million or 32% is the result of salary and headcount decreases, a reduction in stock-based compensation expense and further cost reduction initiatives company wide. We plan to institute further actions during 2014 that may further reduce our quarterly levels of SG&A expense.

Interest Income

Interest income decreased to $5,000 for the nine months ended September 30, 2014 from approximately $7,000 in the nine months ended September 30, 2013. The decrease is primarily the result of smaller cash balances available to invest during 2014.

Interest Expense

Interest expense for the nine months ended September 30, 2014 was $0.5 million compared with $0.6 million in the nine months ended September 30, 2013 and currently represents interest expense on the 4% Senior Convertible Debentures issued in July 2014 and the amortization of the related debt discount compared with the interest and other expenses related to the loan from Hercules Technology entered into in March 2013 and paid in full on September 10, 2013 (See Footnote 9 “DEBT”).

Change in Fair Value of Warrant Liability

The change in fair value of our warrant liability is a benefit of $7.2 million for the nine months ended September 30, 2014 from an expense of $0.1 million for the nine months ended September 30, 2013. The benefit in each period resulted primarily from a decrease in our stock price.

 

15


Table of Contents

Registration Rights Liquidated Damages

In connection with the February 2014 financing (see above), we granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. In addition to the registration rights, the Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. We were unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of $3.4 million.

Other Income

Other income for the nine month periods ended September 30, 2014 and 2013 was $0.1 million and $15,000, respectively, and consists of royalty income we earn each quarter from Kavo Dental GmbH on the sale/licensing of our DIFOTI product. During 2014, we received back royalty payments on actual unit sales compared with the minimum royalty payment of $20,000 we recorded in 2013.

Summary of Cash Flow Activities

Our cash and cash equivalents at September 30, 2014 are liquid investments in money market accounts and deposits with commercial banks, which are held in amounts that substantially exceed Federal Deposit Insurance Corporation (“FDIC”) limits.

Cash Flows from Operating Activities

Net cash used in operations was approximately $14.7 million for the nine months ended September 30, 2014. For the corresponding period in 2013, net cash used in operations was approximately $15.5 million. In both periods, cash used in operations was attributable to net losses after an adjustment for non-cash charges, principally related to the change in fair value of warrant liability, inventory reserves, depreciation/amortization and share-based compensation, and other changes in operating assets and liabilities. Net cash used in operations for the period ended September 30, 2014 includes $3.4 million in liquidating damages that were paid to the Purchasers in our February 2014 financing.

Cash Flows from Investing Activities

For the nine months ended September 30, 2014, $17,000 was provided by sales of our fixed assets, and for the nine months ended September 30, 2013, $4.9 million of net cash was used in our investing activities for the purchase of fixed assets, which consist mainly of the MelaFind® systems.

Cash Flows from Financing Activities

For the nine months ended September 30, 2014, approximately $25.3 million was provided by our financing activities representing the net proceeds of $11.5 million from our February 2014 financing and approximately $13.8 million in net proceeds from issuance of Senior Secured Debentures in July 2014. For the nine months ended September 30, 2013, approximately $15.8 million was provided by the net proceeds from our public offering offset by approximately $0.6 million in charges associated with borrowing and early repayment of debt.

Because of the numerous risks and uncertainties associated with the commercialization of medical devices such as MelaFind®, our future development plans, and the costs of operating our Company, we are unable to estimate the exact amounts of future capital outlays and operating expenditures. Our future funding requirements will depend on many factors, including, but not limited to:

 

    the cost of commercialization activities, including medical, marketing and sales expenses, contract manufacturing and inventory expenses and support of the current domestic direct sales force and conducting activities in Germany;

 

    the cost of transitioning our operations and implementing a refocused marketing strategy;

 

    sales of MelaFind® units which will depend upon reimbursement amounts physicians are able to obtain from Medicare and third party payers;

 

    the costs of maintaining regulatory approval;

 

    the success of our research and development efforts in product development and enhancement, and meeting competitive services and technologies;

 

    the schedule, costs, and results of our clinical trials and studies, including the PAS;

 

    the costs of maintaining or potentially building our inventory and other manufacturing expenses;

 

16


Table of Contents
    our ability to establish and maintain any collaborative, licensing or other arrangements, and the terms and timing of any such arrangements;

 

    the costs involved in defending any patent infringement actions or other litigation claims brought against us by third parties; and

 

    the costs of filing, prosecuting, defending and enforcing any patent claims or other rights.

Contractual Obligations

The following table summarizes our outstanding contractual obligations as of September 30, 2014, and the effect those obligations are expected to have on our liquidity and cash flows in future periods:

 

     Total      Less than
1 year
     1-3 years  

Operating leases

   $ 1,075,221       $ 477,876       $ 597,345   

Our long-term operating lease obligations represent a non-cancelable operating lease for our laboratory, assembly, and office space. The lease on approximately 21,700 square feet of space expires in December 2016.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our judgments related to accounting estimates. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 1 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013, we believe that the following accounting policies and significant judgments and estimates relating to revenue recognition, stock-based compensation charges, and fair value of warrants are most critical to aid you in fully understanding and evaluating our reported financial results.

Revenue Recognition

We consider revenue to be earned when all of the following criteria are met: persuasive evidence a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. Our agreements with dermatologists regarding the MelaFind® system combine the elements noted above with a future service obligation. Under our leased-based model, while the Company is required to place the MelaFind® systems with dermatologists for their exclusive use, ownership of the MelaFind® systems remained with the Company.

During 2013 and the first nine months of 2014, under the old leased-based method, we generated revenue from usage based on the number of patient sessions and lesions examined. Electronic record cards activate the MelaFind® system, capture data and store the data. Additionally, we typically charged an initial installation fee for each MelaFind® system which covered training, delivery, initial supplies, maintenance and the right to use the MelaFind® system. In accordance with the accounting guidance regarding multiple-element arrangements, we allocated total contract consideration to each element based upon the relative standalone selling prices of each element, and recognized the associated revenue for each element as delivery occurred or over the related service period, generally expected to be two years. Revenues associated with undelivered elements were deferred until delivery occurred or services are rendered. The significant judgments we made related to allocation of the contract consideration to each element whereby changes in the standalone selling price could impact the amount of revenue recognized in a specific period and estimates of uncollectible accounts receivables.

In December 2013, we changed our business model from a leased-based model to a sales-based model for the MelaFind® system. Therefore, we will recognize revenues for product sales when title and risk of loss transfers to customers, which is after installation and training, and when reliable estimates of sales allowances and warranties can be made and collectability is reasonably assured. We will regularly review the information related to these estimates and adjust the reserves accordingly.

 

17


Table of Contents

Stock-Based Compensation

We record compensation expense associated with stock options, restricted stock awards and other forms of equity compensation in accordance with FASB Accounting Standards Codification (“ASC”) 718, Compensation-Stock Compensation. The fair value of an equity award is determined at the date of grant using the Black-Scholes Model and the fair value of the equity award is expensed over the service period. The most significant inputs used to value an equity award include current stock price, the amount the employee must pay to acquire the equity award, volatility rate, interest rate and estimated term. For equity awards that vest upon achieving a defined milestone, the underlying compensation charge is recorded, when it is probable that the milestone will be achieved. It is then amortized over the estimated period to satisfy vesting requirements. The probability of vesting is updated at each reporting period and compensation is adjusted accordingly. The significant judgments relate to the assumptions used in the valuation model to determine the fair value of the equity instrument including the volatility rate, term and interest rate. Any increases (decreases) in the volatility rate, the term or the interest rate would increase (decrease) the value of the equity instrument and the corresponding compensation expense recognized each period. Estimates of performance based awards vesting can also have a significant impact on recognized stock compensation as the likelihood of a performance based award vesting can change from period-to-period with changes in estimates included in current period operations.

Fair Value Measurements

We make fair value measurements for financial instruments in accordance with the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures”. This standard defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 permits an entity to measure certain financial assets and financial liabilities at fair value with changes in fair value recognized in earnings each period.

ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are directly or indirectly observable for the asset or liability. Such inputs include quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, or inputs derived principally from or corroborated by observable market data by correlation or other means. Level 3 inputs are unobservable inputs for the asset or liability. Such inputs are used to measure fair value when observable inputs are not available.

Warrant Liability

We account for the 685,715 common stock warrants issued in connection with the October 31, 2013 financing and the 1,329,731 common stock warrants issued in connection with the February 5, 2014 financing in accordance with the guidance contained in ASC 815-40-15-7D, “Contracts in Entity’s Own Equity”. Under that provision these warrants do not meet the criteria for equity treatment and must be recorded as a liability because they have non-standard terms in relation to a fundamental transaction and require a net cash settlement upon a change in control. Accordingly, we classified the warrant instrument as a liability at its fair value and adjust the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised or expiration, and any change in fair value is recognized in the Company’s statements of operations. The fair value of warrants issued by the Company in connection with the transaction has been estimated using an option pricing model. We also accounted for 69,321 common stock warrants that were issued in connection with our debt financing during the nine months ended September 30, 2013, as a liability until we increased our authorized number of shares at the 2013 Annual Meeting of Stockholders and then reclassified those warrants into equity.

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.

Recent Accounting Pronouncements

In August 2014, the FASB issued ASU No. 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for annual periods ending after December 15, 2016. Early adoption is permitted. We are currently evaluating the new guidance to determine the impact the adoption of this guidance will have on our results of operations, cash flows or financial condition.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will

 

18


Table of Contents

require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016 and interim periods within those periods. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. We are currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Our exposure to market risk is confined to our cash, cash equivalents, and short-term investments. We invest in high-quality financial instruments, primarily money market funds, with the average effective duration of the portfolio within one year which we believe are subject to limited credit risk. We currently do not hedge interest rate exposure. Due to the short-term nature of our investments, we do not believe that we have any material exposure to interest rate risk arising from our investments. The Company is exposed to credit risks in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.

ITEM 4.

Controls and Procedures

Evaluation of disclosure controls and procedures

Based on their evaluation as of September 30, 2014, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, were effective to ensure that the information required to be disclosed by us in this Quarterly Report on Form 10-Q was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and Form l0-Q, and that such information was accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Change in internal control over financial reporting

There were no changes in our internal control over financial reporting during the three and nine months ended September 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the effectiveness of controls

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material in which case we will make separate disclosure as required.

 

Item 1A. Risk Factors

Our business and operations entail a variety of serious risks and uncertainties, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013. In addition, (i) the first two following risk factors have materially changed during the nine months ended September 30, 2014 and replace and supersede the risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2013 and (ii) the last two following risk factors are hereby added:

We have incurred losses for a number of years, and anticipate that we will incur continued losses for the foreseeable future.

Since 1999, we have primarily financed our operations through the sale of our equity securities and have devoted substantially all of our resources to research, development and commercialization of the MelaFind® system. Our net loss for the three and nine months ended September 30, 2014 was approximately $2.3 million and $9.6 million, respectively, and as of September 30, 2014, we had an accumulated deficit of approximately $177.8 million. Our expenses will increase in connection with our continued commercialization

 

19


Table of Contents

and development activities related to MelaFind®. We expect to incur additional medical, marketing and sales expenses in the near future and to incur additional contract manufacturing and inventory expenses in the future which will require additional funding. We expect to incur additional expenses continuing to transition our operations and implementing our refocused marketing strategy. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future and cannot determine at this time when we will generate any significant revenues if at all. These losses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity.

We may be unable to continue commercialization of MelaFind® or other products without additional funding

As of September 30, 2014, we had approximately $14.5 million in cash and cash equivalents and cash used in operations for the nine months ended September 30, 2014 was approximately $14.7 million. Our total liabilities at September 30, 2014 were approximately $9.1 million. In July 2014, we raised additional net proceeds of approximately $13.8 million through the issuance of 4% senior secured convertible debentures due July 2019. The debentures are convertible at any time into an aggregate of approximately 5.8 million shares of our common stock at a price of $2.565 per share. Our obligations under the debentures are secured by a first priority lien on all of our intellectual property. We expect to incur significant losses for the foreseeable future and may not achieve operating profits or positive cash flows from operations. Our ability to fund its operations is not assured and will be impacted by market acceptance of the MelaFind® system and the related growth in revenues, cost cutting measures that are in place currently or may be put into place in the future and our ability to raise capital in the future. We anticipate that long term, we will need to raise substantial funds to broaden the commercialization and awareness of the MelaFind® system. The timing and amount of any additional funding we may require will be affected by the commercial success of our MelaFind® product. For example, the funding, if available, could be in the form of either additional equity, equity-linked or debt financing. There can be no assurances that we will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term. Any additional funding that we may obtain in the future could be dilutive to common stockholders and could provide new investors with rights and preferences senior to common stockholders. In the event that we are unable to achieve profitable operations and/or raise additional funds, we would need to further reduce current operations and expansion plans would be cancelled or ultimately we may need to terminate operations. Failure to fund operations will have a material adverse effect on our business and our stock price.

Risks Relating to the July 2014 Private Placement Transaction

The Debentures contain covenants that could limit our financing options and liquidity position, which would limit our ability to grow our business.

The Debentures contain certain covenants and representations limiting our ability to incur additional indebtedness, other than specified permitted indebtedness, and from entering into or creating any liens on our assets, other than certain permitted liens. These restrictions may limit our ability to obtain additional financing, withstand downturns in our business or take advantage of business opportunities. Moreover, future debt financing we may seek may contain terms that include more restrictive covenants, may require repayment on an accelerated schedule or may impose other obligations that limit our ability to grow our business, acquire needed assets, or take other actions we might otherwise consider appropriate or desirable.

Our failure to avoid events of default as defined in the Debentures could require us to redeem such Debentures at a premium.

The Debentures provide that, upon the occurrence of an “Event of Default,” the interest rate on the Debentures increases to 12%. Events of Default under the Debentures include, among other things: (1) suspension or removal from the NASDAQ Capital Market or other permissible trading market for specified time periods; (2) failure to pay principal, interest, late charges and other amounts due under the Debentures; (3) certain events of bankruptcy or insolvency of our company; and (4) failure to make payment with respect to any indebtedness in excess of $150,000 to any third party, or the occurrence of a default or event of default under certain agreements binding our company.

Our ability to avoid such Events of Default may be affected by changes in our business condition or results of our operations, or other events beyond our control. If we were to experience an Event of Default and the holders elected to have us redeem their Debentures, we may not have sufficient resources to do so, and we may have to seek additional debt or equity financing to cover the costs of redeeming the Debentures. Any additional debt or equity financing that we may need may not be available on terms favorable to us, or at all.

 

20


Table of Contents
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We previously reported sales of unregistered equity securities in our Form 8-K current report we filed with the SEC on July 23, 2014.

 

Item 3. Defaults Upon Senior Securities

Not applicable

 

Item 4. Mine Safety Disclosures

Not applicable

 

Item 5. Other Information

 

(a) Not applicable

 

(b) Not applicable

 

Item 6. Exhibits

 

Exhibit

Number

   Exhibit Title
    3.1    Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to our Registration Statement on Form S-3 (File No. 333-167113), as filed on May 26, 2010).
    3.2    Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to our Registration Statement on Form S-3 (File No. 333-189118), as filed on June 5, 2013).
    3.3    Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K (File No. 000-51481), filed on July 10, 2014).
    3.4    Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K (File No. 000-51481), filed on February 3, 2014).
    3.5    Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K (File No. 000-51481), filed on July 23, 2014).
    4.1    Form of Series A/B Warrant to purchase common stock issued to July 2014 Investors and Placement (Incorporated by reference to Exhibit 4.1 contained in our Current Report on Form 8-K (File No. 000-51481), filed on July 23, 2014)
    4.2    Form of Senior Secured Convertible Debenture issued to Purchasers (Incorporated by reference to Exhibit 4.2 contained in our Current Report on Form 8-K (File No. 000-51481), filed on July 23, 2014).
  10.1#    Securities Purchase Agreement by and among the Company and the Purchasers (as defined therein), dated July 21, 2014.
  10.2#    Registration Rights Agreement by and among the Company and the Purchasers (as defined therein), dated July 21, 2014.
  10.3#    Security Agreement by and among the Company, the Guarantors (as defined therein) and the investors, dated July 21, 2014.
  10.4    Engagement Letter Agreement by and between the Company and H.C. Wainwright & Co. LLC, dated June 13, 2014 (Incorporated by reference to Exhibit 10.4 contained in our Registration Statement on Form S-3 (File No. 333-198249), filed on August 19, 2014).
  31.1#    Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
  31.2#    Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
  32.1#    Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.1#    Interactive Data File

 

# Filed herewith

 

21


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

MELA SCIENCES, INC.
By:  

/s/ Robert W. Cook

  Robert W. Cook
 

Chief Financial Officer

(Principal Financial Officer)

Date: November 14, 2014

 

22


Table of Contents

EXHIBIT INDEX

 

Exhibit

No.

   Description
    3.1    Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to our Registration Statement on Form S-3 (File No. 333-167113), as filed on May 26, 2010).
    3.2    Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to our Registration Statement on Form S-3 (File No. 333-189118), as filed on June 5, 2013).
    3.3    Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K (File No. 000-51481), filed on July 10, 2014).
    3.4    Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K (File No. 000-51481), filed on February 3, 2014).
    3.5    Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K (File No. 000-51481), filed on July 23, 2014).
    4.1    Form of Series A/B Warrant to purchase common stock issued to July 2014 Investors and Placement (Incorporated by reference to Exhibit 4.1 contained in our Current Report on Form 8-K (File No. 000-51481), filed on July 23, 2014)
    4.2    Form of Senior Secured Convertible Debenture issued to Purchasers (Incorporated by reference to Exhibit 4.2 contained in our Current Report on Form 8-K (File No. 000-51481), filed on July 23, 2014).
  10.1    Securities Purchase Agreement by and among the Company and the Purchasers (as defined therein), dated July 21, 2014.
  10.2    Registration Rights Agreement by and among the Company and the Purchasers (as defined therein), dated July 21, 2014.
  10.3    Security Agreement by and among the Company, the Guarantors (as defined therein) and the investors, dated July 21, 2014.
  10.4    Engagement Letter Agreement by and between the Company and H.C. Wainwright & Co. LLC, dated June 13, 2014 (Incorporated by reference to Exhibit 10.4 contained in our Registration Statement on Form S-3 (File No. 333-198249), filed on August 19, 2014).
  31.1    Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
  31.2    Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
  32.1    Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.1    Interactive Data File

 

23